Immunogenicity and safety of a liquid combination of DT-PRP-T vs lyophilized PRP-T reconstituted with DTP

Vaccine

Volumn 15, Issue 2, 1997, Pages 149-154

  Amir, Jacob ^a   Melamed, Rimma ^b   Bader, Juma ^a   Ethevenaux, Chantal ^c   Fritzell, Bernard ^c   Cartier, Jean R ^c   Arminjon, François ^c   Dagan, Ron ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c Sérums et Vaccins ^*  (France)

Author keywords

Combination vaccines; Haemophilus influenzae b; Immunization

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ARTICLE; BACTERIAL MENINGITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIPHTHERIA; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MUSCLE HYPOTONIA; NORMAL HUMAN; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TETANUS; VACCINATION;

ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; FREEZE DRYING; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; SODIUM CHLORIDE; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 0031081382     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00162-4     Document Type: Article

References (22)

1. 1 Black, S.B. and Shinefield, H.R. The Kaiser Permanente Vaccine Study Group. Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large HMO population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. Pediatr. Infect. Dis. J. 1992, 11, 610-613
2. 2 King, G.E. and Hadler, S.C. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr. Infect. Dis. J. 1994, 13, 394-407
3. 3 Dagan, R., Botujansky, C., Watemberg, N. et al. Safety and immunogenicity in young infants of Haemophilus b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Pediatr. Infect. Dis. J. 1994, 13, 356-361
4. 4 Watemberg, N., Dagan, R., Arbelli, Y. et al. Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr. Infect. Dis. J. 1991, 10, 758-761
5. 5 Barra, A., Dagan, R., Preud'homme, J.L., Bajart, A. and Fritzell, B. Characterization of the serum antibody response induced by Haemophilus influenzae type b tetanus protein-conjugate vaccine in infants receiving a DTP-combined vaccine from 2 months of age. Vaccine 1993, 11, 1003-1006
6. 6 Ferrecio, C., Clemens, J., Avendano, A. et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccaride tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age. Pediatr. Infect. Dis. J. 1991, 10, 764-771
7. 7 Paradiso, P., Hogerman, D., Madore, D. et al. Safety and immunogenicity in infants of a tetravales vaccine composed of HbOC and DTP (Abstract). Pediatr. Res. 1992, 31, 174A
8. 8 Kaplan, S.L., Lauer, B.A., Ward, M.A. et al. Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. J. Pediatr. 1994, 124, 323-327
9. 9 Kovel, A., Wald, E.R., Guerra, N., Serdy, C. and Meschievitz, K. Safety and immunogenicity of a cellular diphtheria-tetanus-pertussis and Haemophilus conjugate vaccines given in a combination or separate injection sites. J. Pediatr. 1992, 120, 84-87
10. 10 Scheifele D., Barreto L., Meekison W., Guasparini R. and Friesen B. Assessment of Haemophilus influenzae type b tetanus toxoid conjugate vaccine given concurrently or mixed with diphtheria-pertussis-tetanus vaccine in healthy infants (Abstract 985). Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October, 1992
11. 11 Shinefield H., Black S., Adelman T., Ensor K. and Hogerman D. Safety and immunogenicity of DTaP-HbOC - a combined oligosaccharide conjugate Haemophilus influenzae type b and a cellular DTP vaccine in toddlers (Abstract 306). Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October, 1992
12. 12 Avendano, D.O.A., Ferreccio, C., Lagos, R. et al. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serological response to diphtheria, tetanus, or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr. Infect. Dis. J. 1993, 12, 638-643
13. 13 Scheifele, D., Barreto, L., Meekison, W., Guasparini, R. and Friesen, B. Can Haemophilus influenzae type-b tetanus toxoid conjugate vaccine be combined with diphtheria toxoid, pertussis vaccine, tetanus toxoid?. Can. Med. Assoc. J. 1993, 149, 1105-1111
14. 14 Clemens, J.D., Ferreccio, C., Levine, M.M. et al. Impact of Haemophilus influenzae type B polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. J. Am. Med. Assoc. 1992, 267, 673-678
15. 15 Gold, R., Scheitele, D., Barreto, L. et al. Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria-tetanus-toxoids-pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr. Infect. Dis. J. 1994, 13, 348-355
16. 16 Black, S.B., Shinefied, H.R., Ray, P. et al. Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diphtheria-tetanus toxoids-pertussis vaccine in infancy. Pediatr. Infect. Dis. J. 1993, 12, 981-985
17. 17 Paradiso, P., Hogerman, D., Madore, D.V. Safety and immunogenicity of a combined diptheria, tetanus, pertussis and Haemophilus influenza type b vaccine in young infants. Pediatr. 1993, 92, 827-832
18. 18 Farr, R.S. A quantitative immunochemical measure of the primary interaction between I* SA and antibody. J. Infect. Dis. 1958, 103, 239-269
19. 19 Greenwood, F.C., Hunter, W.H. and Glover, J.S. The preparation of 131 iodine labeled human growth hormone of high specific radioactivity. Biochem. J. 1963, 89, 114-123
20. 20 Fayet M.T., Vincent-Flaquet J.C., Tayot J.L. and Trian R. Interest of the evaluation of tetanus antibodies by RIA. Presented at the Fifth International Conference on Pertussis, Ronely, Sweden, 18-23 June, 1978
21. 21 Kendrick P.I., Lawson G. McL. and Miller J.J. Diagnostic Procedures and Reagents, Vol. 136. American Public Health Association, New York, 1950
22. 22 Fritzell, B. and Plotkin, S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J. Pediatrics 1992, 121, 355-362